Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

208 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
[Risk factors for hepatitis C among injecting drug users in Oslo].
Dalgard O, Egeland A, Ervik R, Vilimas K, Skaug K, Steen TW. Dalgard O, et al. Tidsskr Nor Laegeforen. 2009 Jan 15;129(2):101-4. doi: 10.4045/tidsskr.09.35002. Tidsskr Nor Laegeforen. 2009. PMID: 19151801 Free article. Norwegian.
Recommendations for the management of hepatitis C virus infection among people who inject drugs.
Robaeys G, Grebely J, Mauss S, Bruggmann P, Moussalli J, De Gottardi A, Swan T, Arain A, Kautz A, Stöver H, Wedemeyer H, Schaefer M, Taylor L, Backmund M, Dalgard O, Prins M, Dore GJ; International Network on Hepatitis in Substance Users. Robaeys G, et al. Among authors: dalgard o. Clin Infect Dis. 2013 Aug;57 Suppl 2:S129-37. doi: 10.1093/cid/cit302. Clin Infect Dis. 2013. PMID: 23884061
Recommendations for the management of hepatitis C virus infection among people who inject drugs.
Grebely J, Robaeys G, Bruggmann P, Aghemo A, Backmund M, Bruneau J, Byrne J, Dalgard O, Feld JJ, Hellard M, Hickman M, Kautz A, Litwin A, Lloyd AR, Mauss S, Prins M, Swan T, Schaefer M, Taylor LE, Dore GJ; International Network for Hepatitis in Substance Users. Grebely J, et al. Among authors: dalgard o. Int J Drug Policy. 2015 Oct;26(10):1028-38. doi: 10.1016/j.drugpo.2015.07.005. Epub 2015 Jul 17. Int J Drug Policy. 2015. PMID: 26282715 Free PMC article.
Hepatitis C reinfection after sustained virological response.
Midgard H, Bjøro B, Mæland A, Konopski Z, Kileng H, Damås JK, Paulsen J, Heggelund L, Sandvei PK, Ringstad JO, Karlsen LN, Stene-Johansen K, Pettersson JH, Dorenberg DH, Dalgard O. Midgard H, et al. Among authors: dalgard o. J Hepatol. 2016 May;64(5):1020-1026. doi: 10.1016/j.jhep.2016.01.001. Epub 2016 Jan 11. J Hepatol. 2016. PMID: 26780289 Clinical Trial.
HCV epidemiology in high-risk groups and the risk of reinfection.
Midgard H, Weir A, Palmateer N, Lo Re V 3rd, Pineda JA, Macías J, Dalgard O. Midgard H, et al. Among authors: dalgard o. J Hepatol. 2016 Oct;65(1 Suppl):S33-S45. doi: 10.1016/j.jhep.2016.07.012. J Hepatol. 2016. PMID: 27641987 Free article. Review.
Contradictory advice for people who inject drugs in the 2016 EASL Recommendations on Treatment of Hepatitis C.
Grebely J, Swan T, Hickman M, Bruneau J, Bruggmann P, Dalgard O, Litwin A, Backmund M, Dore GJ; International Network for Hepatitis in Substance Users. Grebely J, et al. Among authors: dalgard o. J Hepatol. 2017 May;66(5):1101-1103. doi: 10.1016/j.jhep.2016.12.028. Epub 2017 Feb 3. J Hepatol. 2017. PMID: 28167323 Free PMC article. No abstract available.
208 results